Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles

Executive Summary

Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant

You may also be interested in...

Genzyme, Icahn Call Off Proxy Fight With Compromise Agreement

In exchange for withdrawing its proxy slate and agreeing to back Genzyme's nominees, Icahn Partners get two seats on biotech's board.

Genzyme, Industry Analysts Relieved By Particulars In Draft Consent Decree

Unveiling its first-quarter financial results, Genzyme reports significant year-over-year sales decreases for Cerezyme and Fabrazyme.

Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn

Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts